关键词：JPND；神经变性疾病；神经元；逐步退化；遗传继承；心理健康；严重影响
摘 要：According to the EU JPND, neurodegenerative diseases are a group of disorders that cause progressive degeneration of the neurons in the brain. These incurable disorders are genetically inherited or of unknown etiology and have severe debilitating effects causing ataxia and dementia in people and having a serious impact on their mental health. These diseases also restrict several bodily activities, such as balance, movement, speaking, breathing, and heart function. Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, and epilepsy are some of the neurodegenerative diseases.Huntington's disease and amyotrophic lateral sclerosis are rare disorders, accounting for a minor share of the market. Alzheimer's and Parkinson's diseases are more prevalent and account for a major share of the market.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1.1 Avonex/Rebif

04.1.2 Plegridy

04.1.3 Tecfidera

04.1.4 Tysabri

04.1.5 Comtan

04.1.6 Stalevo

04.1.7 Exelon/Exelon Patch

04.1.8 Extavia

04.1.9 Gilenya

04.1.10 Cerebyx

04.1.11 Dilantin-125

04.1.12 Lyrica

04.1.13 Neurontin

04.1.14 Zarontin

04.1.15 Azilect

04.1.16 Copaxone

04.1.17 Keppra/Keppra XR

04.1.18 Neupro

04.1.19 Vimpat

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Introduction

07. Market Landscape

07.1 Market Overview

07.2 Market Size and Forecast

07.3 Five Forces Analysis

08. Segmentation of Global Neurodegenerative

Diseases Market by Type of Disease

09. Global Multiple Sclerosis Market

09.1 Multiple Sclerosis: Overview

09.1.1 About the Disease

09.1.2 Symptoms

09.1.3 Etiology

09.1.4 Epidemiology

09.1.5 Economic Burden

09.2 Market Overview

09.3 Market Size and Forecast

09.4 Multiple Sclerosis Market in US

09.4.1 Market Size and Forecast

10. Global Alzheimer's Disease Market

10.1 Alzheimer's Disease: Overview

10.1.1 About the Disease

10.1.2 Dementia

10.1.3 Epidemiology and Forecast

10.1.4 Types of Dementia

10.1.5 Global Burden

10.1.6 Etiology

10.1.7 Cost of Care

10.1.8 Alzheimer's Disease and Caregiving

10.2 Market Overview

10.3 Market Size and Forecast

11. Global Epilepsy Market

11.1 Epilepsy: Overview

11.1.1 About the Disease

11.1.2 Etiology

11.1.3 Types of Epilepsy

11.1.4 Symptoms

11.1.5 Epidemiology

11.1.6 Economic Burden

11.2 Market Overview

11.3 Market Size and Forecast

11.4 Epilepsy Market in US

11.4.1 Market Size and Forecast

11.5 Epilepsy Market in Europe

11.5.1 Market Size and Forecast

11.6 Epilepsy Market in Japan

11.6.1 Market Size and Forecast

12. Global Parkinson's Disease Market

12.1 Parkinson's Disease: Overview

12.1.1 About the Disease

12.1.2 Symptoms

12.1.3 Etiology

12.1.4 Epidemiology

12.1.5 Economic Burden

12.2 Market Overview

12.3 Market Size and Forecast

13. Global Huntington's Disease Market

13.1 Huntington's Disease: Overview

13.1.1 About the Disease

13.1.2 Symptoms

13.1.3 Etiology

13.1.4 Prevalence of Huntington's Disease

13.1.5 Pipeline Portfolio

13.1.6 Economic Burden

13.2 Market Overview

13.3 Market Size and Forecast

14. Global Amyotrophic Lateral Sclerosis Market

14.1 Amyotrophic Lateral Sclerosis: Overview

14.1.1 About the Disease

14.1.2 Types of Amyotrophic Lateral Sclerosis

14.1.3 Etiology and Pathophysiology

14.1.4 Symptoms

14.1.5 Epidemiology

14.1.6 Diagnosis

14.1.7 Pipeline Portfolio

14.2 Market Overview

14.3 Market Size and Forecast

15. Segmentation of Global Neurodegenerative

Diseases Market by Type of Molecule

15.1 Biologics

15.2 Small Molecules

16. Segmentation of Global Neurodegenerative

Diseases Market by Route of Administration

16.1 Oral

16.2 Parenteral

16.3 Topical

17. Geographical Segmentation

18. Buying Criteria

19. Market Growth Drivers

20. Drivers and their Impact

21. Market Challenges

22. Impact of Drivers and Challenges

23. Market Trends

24. Trends and their Impact

25. Vendor Landscape

25.1 Competitive Scenario

25.1.1 Key News

25.1.2 Mergers and Acquisitions

25.2 Market Share Analysis 2014

25.2.1 Competitive Assessment of Major Drugs

25.2.2 Biogen Idec

25.2.3 Pfizer

25.2.4 Teva Pharmaceutical

25.2.5 Novartis

25.2.6 Merck Serono

25.2.7 UCB

25.3 Other and Potential Future Prominent Vendors

26. Key Vendor Analysis

26.1 Biogen Idec

26.1.1 Key Facts

26.1.2 Business Overview

26.1.3 Business Segmentation by Revenue 2013

26.1.4 Geographical Segmentation by Revenue 2013

26.1.5 Business Strategy

26.1.6 Key Developments

26.1.7 SWOT Analysis

26.2 Merck Serono

26.2.1 Key Facts

26.2.2 Business Overview

26.2.3 Geographical Segmentation by Revenue 2013

26.2.4 Business Strategy

26.2.5 Recent Developments

26.2.6 SWOT Analysis

26.3 Novartis

26.3.1 Key Facts

26.3.2 Business Description

26.3.3 Business Segmentation

26.3.4 Revenue by Business Segmentation

26.3.5 Revenue Comparison 2012 and 2013

26.3.6 Sales by Geography

26.3.7 Business Strategy

26.3.8 Key Developments

26.3.9 SWOT Analysis

26.4 Pfizer

26.4.1 Key Facts

26.4.2 Business Overview

26.4.3 Business Segmentation by Revenue 2013

26.4.4 Business Segmentation by Revenue 2012 and 2013

26.4.5 Geographical Segmentation by Revenue

26.4.6 Business Strategy

26.4.7 Key Developments

26.4.8 SWOT Analysis

26.5 Teva Pharmaceutical

26.5.1 Key Facts

26.5.2 Business Overview

26.5.3 Business Segmentation

26.5.4 Business Segmentation by Revenue 2013

26.5.5 Business Segmentation by Revenue 2012 and 2013

26.5.6 Sales by Geography

26.5.7 Business Strategy

26.5.8 Key Developments

26.5.9 SWOT Analysis

26.6 UCB

26.6.1 Key Facts

26.6.2 Business Overview

26.6.3 Product Segmentation by Revenue 2013

26.6.4 Product Segmentation by Revenue 2012 and 2013

26.6.5 Geographical Segmentation by Revenue 2013

26.6.6 Business Strategy

26.6.7 Recent Developments

26.6.8 SWOT Analysis

27. Other Reports in this Series